Vascular Genetic Variants and Ischemic Stroke Susceptibility in Albanians from the Republic of Macedonia
DOI:
https://doi.org/10.3889/oamjms.2016.114Keywords:
ischemic stroke, vascular genetic variations, association, Albanians, Republic of MacedoniaAbstract
BACKGROUND: Acute first-ever ischemic stroke (FIS) is a heterogeneous, polygenic disorder. The contribution of vascular genetic variants as inherited causes of ischemic stroke has remained controversial.
AIM: To examine the association of genetic variants in vascular factors with the occurrence of FIS.
MATERIAL AND METHODS: The current research was performed in a group of 39 patients with FIS (study group) and 102 healthy volunteers (control group). We analyzed the prevalence of vascular genetic variants in following genes: factor V, prothrombin, methylenetetrahydrofolate reductase (MTHFR), factor XIII, plasminogen activator 1, endothelial protein C receptor (EPCR), apolipoprotein B, apolipoprotein E, β-fibrinogen, human platelet antigen 1, angiotensin-converting enzyme (ACE), endothelial nitric oxide synthase (eNOS) and lymphotoxin alpha.
RESULTS: It was found that heterozygous LTA 804C>A and FXIII V34L Leu/Leu were significantly more frequent in patients with FIS than in control group (p = 0.036 and p = 0.017, respectively). The frequency of FXIII V34L Val/Val was significantly lower in patients with FIS than in control group (p = 0.020). Other frequencies of vascular gene variants in patients with FIS and in control group were not significantly different.
CONCLUSIONS: This is the first comprehensive study to present data indicating that polymorphism of vascular genes in the prevalence of acute FIS exists in the Albanian population from the Republic of Macedonia. Variations in these genes have been detected in patients with acute FIS, suggesting that their combination might act in a susceptible or protective manner in this Albanian population.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Alrajeh SM, Alkali NH. Genetics of ischemic stroke. Neurosciences. 2008; 13(4): 343-349. PMid:21063358
Hassan A, Markus HS. Genetics and ischaemic stroke. Brain. 2000; 123(9): 1784-1612. http://dx.doi.org/10.1093/brain/123.9.1784 PMid:10960044 DOI: https://doi.org/10.1093/brain/123.9.1784
Meschia JF, Worral BB, Rich SS. Genetic susceptibility to ischemic stroke. Nat Rev Neurol. 2001; 7(7): 368-378. DOI: https://doi.org/10.1038/nrneurol.2011.80
Himabindu G, Rajasekhar D, Latheef K, Sarma PV, Vanajakshamma V, et al. Factor V Leiden mutation is not a predisposing factor for acute coronary syndromes. Indian Heart J. 2012; 64(6): 570-575. http://dx.doi.org/10.1016/j.ihj.2012.07.006 PMid:23253409 PMCid:PMC3860758 DOI: https://doi.org/10.1016/j.ihj.2012.07.006
Nicolaes GA, Bock PE, Segers K, Wildhagen KC, Dahlback B, Rosing J. Inhibition of thrombin formation by active site mutated (S360A) activated protein. J Biol Chem. 2010; 285(30): 22890-900. http://dx.doi.org/10.1074/jbc.M110.131029 PMid:20484050 PMCid:PMC2906281 DOI: https://doi.org/10.1074/jbc.M110.131029
Kim RJ, Becker RC. Association between factor V Leiden, prothrombin mutation G20210A, and MTHFR C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. American Heart Journal. 2004; 146(6): 948-957. http://dx.doi.org/10.1016/S0002-8703(03)00519-2 DOI: https://doi.org/10.1016/S0002-8703(03)00519-2
Mueller T, Marschon R, Dieplinger B, Haidinger D, Gegenhuber A, Poelz W, et al. Factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations are not associated with chronic limb ischemia: the Linz Peripheral Arterial Disease (LIPAD) study. J Vasc Surg. 2005; 41: 808-815. http://dx.doi.org/10.1016/j.jvs.2005.01.039 PMid:15886665 DOI: https://doi.org/10.1016/j.jvs.2005.01.039
Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. Classification of stroke subtypes. Cerebrovasc Dis. 2009; 27: 493-501. http://dx.doi.org/10.1159/000210432 PMid:19342825 DOI: https://doi.org/10.1159/000210432
Della-Morte D, Pacifici F, Rundek T. Genetic susceptibility to cerebrovascular disease. Curr Opin Lipidol. 2016; 27(2): 185-195. http://dx.doi.org/10.1097/MOL.0000000000000275 PMid:26959706 DOI: https://doi.org/10.1097/MOL.0000000000000275
Lusis AJ. Genetic of Atherosclerosis. Trends Genet. 2012; 28(6): 267-275. http://dx.doi.org/10.1016/j.tig.2012.03.001 PMid:22480919 PMCid:PMC3362664 DOI: https://doi.org/10.1016/j.tig.2012.03.001
Biros E, Karan M, Golledge J. Genetic Variation and Atherosclerosis. Current Genomics. 2008; 9:29-42. http://dx.doi.org/10.2174/138920208783884856 PMid:19424482 PMCid:PMC2674308 DOI: https://doi.org/10.2174/138920208783884856
Hanscombe KB, Traylor M, Hysi PG, Bevan S, Dichgans M, Rothwell PM, Worall BB, Seshadri S, Sudlow C, METASTROKE Consortium; Wellcome Trust Case Control Consortium 2, Williams FM, Markus HS, Lewis CM. Genetic Factors Influencing Coagulation Factor XIII B-Subunit Contribute to Risk of Ischemic Stroke. Stroke. 2015; 46(8): 2069-2074. http://dx.doi.org/10.1161/STROKEAHA.115.009387 PMid:26159793 PMCid:PMC4512747 DOI: https://doi.org/10.1161/STROKEAHA.115.009387
Shemirani AH, Antalfi B, Pongrácz E, Mezei ZA, Bereczky Z, Csiki Z. Factor XIII-A subunit Val34Leu polymorphism in fatal atherothromboric ischemic stroke. Blood Coagul Fibrinolysis. 2014; 25(4): 364-368. http://dx.doi.org/10.1097/MBC.0000000000000055 PMid:24686102 DOI: https://doi.org/10.1097/MBC.0000000000000055
Wiklund PG, Nilson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case control studies based on independent cohorts. Stroke. 2005; 36: 1661-1665. http://dx.doi.org/10.1161/01.STR.0000174485.10277.24 PMid:16020771 DOI: https://doi.org/10.1161/01.STR.0000174485.10277.24
Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombothic stroke. Cerebrovasc Dis. 2001; 11: 294-299. http://dx.doi.org/10.1159/000047656 PMid:11385207 DOI: https://doi.org/10.1159/000047656
de Paula Sabino A, Ribeiro DD, Domingueti CP, Dos Santos MS, Gadelha T, Dusse LM, das Gracas Carvalho M, Fernandes AP. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke. Mol Biol Rep. 2011; 38: 5355-5360. http://dx.doi.org/10.1007/s11033-011-0687-4 PMid:21373825 DOI: https://doi.org/10.1007/s11033-011-0687-4
Endler G, Lalouschek W, Exner M, Mitterbauer G, Haring D, Manhalter C. The 4G/4G genotype at nucleotide position -675 in the promoter region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol. 2000; 110: 469-471. http://dx.doi.org/10.1046/j.1365-2141.2000.02164.x PMid:10971410 DOI: https://doi.org/10.1046/j.1365-2141.2000.02164.x
Hoekstra T, Geleijnse JM, Kluft C, Giltay EJ, Kok FJ, Schouten EG. 4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke. 2003; 34: 2822-2828. http://dx.doi.org/10.1161/01.STR.0000098004.26252.EB PMid:14605330 DOI: https://doi.org/10.1161/01.STR.0000098004.26252.EB
Benn M, Nordestgaard BG, Jensen JS, Tybjaerg-Hansen A. Polymorphiss in apoliprotein B and risk of ischemic stroke. J Clin Endocr Metab. 2007; 92: 3611-3617. http://dx.doi.org/10.1210/jc.2007-0221 PMid:17595251 DOI: https://doi.org/10.1210/jc.2007-0221
Somay G, Misirli H, Guler M, CaliÅŸkan N, ErenoÄŸlu YN. Serebrovasculer hastaliklarda apolipoprotein E ve anjiotensin coverting enzim gen polimorfizmi. Turk Beyin Damar Hastaliklari Dergisi. 2002; 8: 113-117.
Liu Y, Pan J, Wang S, Li X, Huang Y. Beta-fibrinogen gene -455 A/G polymorphism and plasma fibrinogen level in Chinese stroke patients. Chin Med J (Engl). 2002; 115(2): 214-216.
Duan H, Cai Y, Sun X. platelet glycoprotein IIb/IIIa polymorphism HPA-3 b/b is associated with increased risk of ischemic stroke in patients under 60 years of age. Med Sci Monit. 2012; 18: 19-24. http://dx.doi.org/10.12659/MSM.882195 PMCid:PMC3560669 DOI: https://doi.org/10.12659/MSM.882195
Saidi S, Mahjoub T, Slamia LB, Ammou SB, Al-Subaie AM, Almawi WY. Polymorphisms of the human platelet alloantigens HPA-1, HPA-2, HPA-3, and HPA-4 in ischemic stroke. Am J Hematol. 2008; 83: 570-573. http://dx.doi.org/10.1002/ajh.21171 PMid:18383324 DOI: https://doi.org/10.1002/ajh.21171
Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: A meta-analysis of 50 case-control studies. Plos One. 2012; 7: 1-9. http://dx.doi.org/10.1371/journal.pone.0046495 DOI: https://doi.org/10.1371/journal.pone.0046495
Kalita J, Somarajan BI, Kumar B, Mittal B, Misra UK. A study of ACE and ADD1 polymorphism in ischemic and hemorrhagic stroke. Clin Chim Acta. 2011; 412: 642-646. http://dx.doi.org/10.1016/j.cca.2010.12.022 PMid:21194526 DOI: https://doi.org/10.1016/j.cca.2010.12.022
Yao YS, Chang WW, Jin YL, He LP. An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with ischemic stroke. Gene. 2013; 528(2): 84-92. http://dx.doi.org/10.1016/j.gene.2013.06.047 PMid:23845784 DOI: https://doi.org/10.1016/j.gene.2013.06.047
Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Hori M, Nakamura Y, Tanaka T. Functional SNPSs in the lymphotoksin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 2002; 32(4): 650-654. http://dx.doi.org/10.1038/ng1047 PMid:12426569 DOI: https://doi.org/10.1038/ng1047
Bajram K. Komparativna analiza na faktorite na rizik i nivnoto vlijanie vrz koncentracijata na plazma homocisteinot vo pojavata na primarniot ishemiÄen cerebrovaskularen insult vo regionot na Tetovo. [doktorska disertacija]. Skopje: Medicinski fakultet, 2013 [Macedonian].
Kamberi B, Kamberi F, Spiroski M. Polymorphisms of Methylenetetrahydrofolate Reductase (MTHFR-677 and MTHFR-1298) Genetic in an Albanian population. European Journal of Neurology. 2014; 21(Suppl. 1):696.
Kamberi B, Kamberi F, Spiroski M. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Albanian patients with acute first-ever ischemic stroke. European Journal of Neurology. 2014; 21(Suppl. 1):535.
Towner P. Isolation of DNA by SDS-proteinase K treatment. In: Brown TA, editor. Essential Molecular Biology. New York: Oxford University Press Inc., 1995:52-53.
Towner P. Basic of methods for isolation of DNA. In: Brown TA, editor. Essential Molecular Biology. New York: Oxford University Press Inc., 1995:47-49.
Spiroski M, Arsov T, Petlichkowski A, Strezova A, Trajkov D, Efinska_Mladenovska O, et al. Case Study: Macedonian human DNA Bank (hDNAMKD) as a source for public health Genetics. in: Georgieva L, Burazeri G, Editors. Health determinants in the scope of new public health. Sofia: Hans Jacobs Company, 2005: 33-44.
Lancaster A, Nelson MP, Meyer D, et al. PyPop: a software framework for population genomics: analyzing large-scale multi locus genotype data. Pac Symp Biocomput. 2003; 514-25. PMid:12603054 PMCid:PMC3891851
Lancaster AK, Single RM, Solberg OD, et al. PyPop update-a software pipeline large-scale multi locus population genomics. Tissue Antigens. 2007; 69(Suppl. 1): 192-7. http://dx.doi.org/10.1111/j.1399-0039.2006.00769.x PMid:17445199 PMCid:PMC4369784 DOI: https://doi.org/10.1111/j.1399-0039.2006.00769.x
Single RM, Meyer D, Mack SJ, et al. 14th International HLA and Immunogenetics workshop: report of progress in methodology, data collection, and analyses. Tissue Antigens. 2007; 69(Suppl. 1): 185-7. http://dx.doi.org/10.1111/j.1399-0039.2006.00767.x PMid:17445197 DOI: https://doi.org/10.1111/j.1399-0039.2006.00767.x
Hadjiev DI, Mineva PP, Vukov MI. Multiple modifiable risk factors for first ischemic stroke: a population-based epidemiological study. European Journal of Neurology. 2003;10:577-582. http://dx.doi.org/10.1046/j.1468-1331.2003.00651.x PMid:12940842 DOI: https://doi.org/10.1046/j.1468-1331.2003.00651.x
Andersen KK, Andersen ZJ, Olsen TS. Age- and gender-specific prevalence of cardiovascular risk factors in 40,102 patients with first-ever ischemic stroke: a Nationwide Danish Study. Stroke. 2010; 41: 2768-2774. http://dx.doi.org/10.1161/STROKEAHA.110.595785 PMid:20966413 DOI: https://doi.org/10.1161/STROKEAHA.110.595785
Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, et al. Lifetime risk of cardiovascular disease. N Engl J Med. 2012; 366: 321-329. http://dx.doi.org/10.1056/NEJMoa1012848 PMid:22276822 PMCid:PMC3336876 DOI: https://doi.org/10.1056/NEJMoa1012848
Nedelthchev K, der Maur TA, Georgiadis D, Arnold M, Caso V, Mattle HP, et al. Ischemic stroke in young adults: predictors of outcome and recurrence. J Neurol Neurosurg Psychiatr. 2005; 76: 191-195. http://dx.doi.org/10.1136/jnnp.2004.040543 PMid:15654030 PMCid:PMC1739502 DOI: https://doi.org/10.1136/jnnp.2004.040543
Putaala J, Metso AJ, Metso TM et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke. 2009; 40: 1195-1203. http://dx.doi.org/10.1161/STROKEAHA.108.529883 PMid:19246709 DOI: https://doi.org/10.1161/STROKEAHA.108.529883
Seshadri S, et al. Parental occurrence of stroke and risk of stroke in their children: the Framingham study. Circulation. 2010;121:1304-1312. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.854240 PMid:20212282 PMCid:PMC2860311 DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.854240
Xin XY, Song YY, Ma JF, Fan CN, Ding JQ, Yang GY, Chen SD. Gene polymorphisms and risk of adult early-onset ischemic stroke: A meta-analysis. Thromb Res. 2009; 124: 619-624. http://dx.doi.org/10.1016/j.thromres.2009.07.007 PMid:19660787 DOI: https://doi.org/10.1016/j.thromres.2009.07.007
MacClellan LR, et al. Familial aggregation of ischemic stroke in young women: the Stroke Prevention in Young Women Study. Genet Epidemiol. 2006; 30: 602-608. http://dx.doi.org/10.1002/gepi.20171 PMid:16868965 DOI: https://doi.org/10.1002/gepi.20171
Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke. 2003; 34: 1364-1369. http://dx.doi.org/10.1161/01.STR.0000069723.17984.FD PMid:12714707 DOI: https://doi.org/10.1161/01.STR.0000069723.17984.FD
Schulz UG, Flossman E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke. 2004; 35: 819-824. http://dx.doi.org/10.1161/01.STR.0000121646.23955.0f PMid:15001788 DOI: https://doi.org/10.1161/01.STR.0000121646.23955.0f
Wang X, et al. A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. Stroke. 2009; 40: 683-695. http://dx.doi.org/10.1161/STROKEAHA.108.524587 PMid:19131662 PMCid:PMC2757095 DOI: https://doi.org/10.1161/STROKEAHA.108.524587
Ariyaratnam R, et al. Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals. PLoS Med. 2007; 4: e131. http://dx.doi.org/10.1371/journal.pmed.0040131 PMid:17455988 PMCid:PMC1876409 DOI: https://doi.org/10.1371/journal.pmed.0040131
Clark JSC, Adler G, Salkic NN, Ciechanowicz A. Allele frequency distribution of 1691G>A F5 (which confers Factor V Leiden) across Europe, including Slavic populations. J Appl Genet. 2013; 54(4): 441-446. http://dx.doi.org/10.1007/s13353-013-0166-9 PMid:23959593 PMCid:PMC3825156 DOI: https://doi.org/10.1007/s13353-013-0166-9
Adler G, Clark JSC, Loniewska B, Czerska E, Salkic NN, Ciechanowicz A. Prevalence of 1691G>A FV mutation in Poland compared with that in other Central, Eastern and South-Eastern European countries. Bosn J Basic Med Sci. 2012; 12(2): 82-87. PMid:22642591 PMCid:PMC4362443 DOI: https://doi.org/10.17305/bjbms.2012.2500
Arsov T, Miladinova D, Spiroski M. Factor V Leiden is associated with higher risk of deep venous thrombosis of large blood vessels. Croat Med J. 2006; 47(3): 433-439. PMid:16758522 PMCid:PMC2080416
Mekaj Y, Zhubi B, Hoxha H, Belegu R, Mekaj A, Miftari E, Belegu M. Prevalence of resistence to activated protein C (APC- resistence) in blood donors in Kosovo. Bosn J Basic Med Sci. 2009; 9: 329-334. PMid:20002000 DOI: https://doi.org/10.17305/bjbms.2009.2789
Atay A, Tekin M, Allajalebeu K, EÄŸin Y, Akar N. The frequency of FV G1691A and PT G20210A mutations in an Albanian population. Turk J Hematol. 2011; 28: 241-242. http://dx.doi.org/10.5152/tjh.2011.64 PMid:27264377 DOI: https://doi.org/10.5152/tjh.2011.64
Erten N, Lopaciuk S, Bykowska K, Kwiecinski H, Mickielewicz A, Czlonkowska A, Mendel T, Kuczynska-Zardzewialy A, Szelagowska D, Windyga J, Schroder W, Herrmann FH, Jedrzejowska H. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahyfrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Hemost. 2001; 7: 346-350. http://dx.doi.org/10.1177/107602960100700418 DOI: https://doi.org/10.1177/107602960100700418
Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol. 2004; 61:1652-1661. http://dx.doi.org/10.1001/archneur.61.11.1652 PMid:15534175 DOI: https://doi.org/10.1001/archneur.61.11.1652
Bhagwat VR, Yadav AS, Rathod IM. Homocysteine, lipid indices and antioxidants in patients with ischaemic heart disease from Maharashtra, India. Singapore Med J. 2009; 50: 418-24. PMid:19421689
Botto L, Yang Q. 5,10-Methyelenetetrahydrofolate reductase gene variants and congenital Anomalies: A HuGE review. Am J Epidemiol. 2000; 151: 862-77. http://dx.doi.org/10.1093/oxfordjournals.aje.a010290 PMid:10791559 DOI: https://doi.org/10.1093/oxfordjournals.aje.a010290
Ho CH. Prevalence of Prothrombin 20210A and Methylenetetrahydrofolate reductase C677T genetic mutation in the Chinese population. Ann Haematol. 2000; 79: 239-42. http://dx.doi.org/10.1007/s002770050586 DOI: https://doi.org/10.1007/s002770050586
Radha Rama Devi A, Govindaiah V, Ramakrishna G, Naushad SM. Prevalence of methylene tetrahydrofolate reductase polymorphism in South Indian population. Current Science. 2004; 86: 440-3.
Refsum H, Yajnik CS, Gadkari M, Schneede J, Vollset SE, Örning L, et al. Hyperhomocysteinemia and elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asian Indians. Am J Clin Nutr. 2001; 74: 233-241. PMid:11470726 DOI: https://doi.org/10.1093/ajcn/74.2.233
Hermann W, Obeid R, Jouma M. Hyperhomocysteinemia and vitamin B12 deficiency are more striking in Syrians than Germans - causes and implications. Atherosclerosis. 2003; 166: 143-150. http://dx.doi.org/10.1016/S0021-9150(02)00320-9 DOI: https://doi.org/10.1016/S0021-9150(02)00320-9
Golbahar J, Fathi Z, Tamadon M. Distribution of 5,10 Methylenetetrahydrofolate reductase (C677T) and its association with red blood cell 5-methyltetrahydrofolate in healthy Iranians. Clin Nutr. 2005; 24: 83-7. http://dx.doi.org/10.1016/j.clnu.2004.07.019 PMid:15681105 DOI: https://doi.org/10.1016/j.clnu.2004.07.019
Eid SS, Rihani GR. Prevalence of factor V Leiden, Prothrombin G20210A and MTHFR C677T mutations in 200 Jordanian Healthy individuals. Clin Lab Sci. 2004; 17: 200-202. PMid:15559724
Trimmer EE. Methylene tetrahydrofolate reductase: biochemical characterization and medical significance. Curr Pharm Des. 2013; 19(14): 2574-2593. http://dx.doi.org/10.2174/1381612811319140008 PMid:23116396 DOI: https://doi.org/10.2174/1381612811319140008
Den Heijer M, Lewington S, Clarke A. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005; 3(2): 292-299. http://dx.doi.org/10.1111/j.1538-7836.2005.01141.x PMid:15670035 DOI: https://doi.org/10.1111/j.1538-7836.2005.01141.x
Giovannetti E, Ugrasena DG, Supriyadi E, et al. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. Leuk Res. 2008; 32: 19-24. http://dx.doi.org/10.1016/j.leukres.2007.02.011 PMid:17395259 DOI: https://doi.org/10.1016/j.leukres.2007.02.011
Alluri RV, Mohan V, Komandur S, Chawda K, Chaudhuri JR, Hasan Q. MTHFR C677T gene mutation as a risk factor for arterial stroke: A hospital based study. Eur J Neurol. 2005; 12: 40-44. http://dx.doi.org/10.1111/j.1468-1331.2004.00938.x PMid:15613145 DOI: https://doi.org/10.1111/j.1468-1331.2004.00938.x
Panigrahi I, Chatterjee T, Biswas A, Behari M, Choudhry PV, Saxena R. Role of MTHFR C677T polymorphism in ischemic stroke. Neurol India. 2006; 54: 48-50. http://dx.doi.org/10.4103/0028-3886.24703 PMid:16679643 DOI: https://doi.org/10.4103/0028-3886.24703
Kalita J, Srivastava R, Bansal V, Agarwal S, Misra UK. MTHFR reductase gene polymorphism in Indian stroke patients. Neurology India. 2006; 54(3): 260-263. http://dx.doi.org/10.4103/0028-3886.27148 PMid:16936384 DOI: https://doi.org/10.4103/0028-3886.27148
Zheng YZ, Tong J, Do XP, Pu XQ, Zhou BT. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chines population. Br J Haematol. 2000; 109: 870-874. http://dx.doi.org/10.1046/j.1365-2141.2000.02112.x PMid:10929044 DOI: https://doi.org/10.1046/j.1365-2141.2000.02112.x
Ucar F, Sommez M, Ovali E, Ozmenoglu M, Karti SS, Yilmaz M et al. MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. Am J Hematol. 2004;76: 40-43. http://dx.doi.org/10.1002/ajh.20050 PMid:15114595 DOI: https://doi.org/10.1002/ajh.20050
Angeline T, Jeyaraj N, Granito S, Tsongalis GJ. Prevalence of MTHFR gene polymorphisms (C677T and A1298C) among Tamilians. Exp Mol Pathol. 2004; 77: 85-88. http://dx.doi.org/10.1016/j.yexmp.2004.04.006 PMid:15351230 DOI: https://doi.org/10.1016/j.yexmp.2004.04.006
Szolnoki Z, Somogyvani F, Kondacs A, Szabo M, Fodor L, Bene J et al. Specific APO E genotypes in combination with the ACE D/D or MTHFR C677T mutation yield an independent genetic risk factor of leukoaraiosis. Acta Neurol Scand. 2004; 109: 222-227. http://dx.doi.org/10.1046/j.1600-0404.2003.00218.x PMid:14763962 DOI: https://doi.org/10.1046/j.1600-0404.2003.00218.x
Spiroski I, Kedev S, Antov S, Arsov T, Krstevska M, Dzhekova-Stojkova S, Bosilkova G, Kostovska S, Trajkov D, Petlichkovski A, Strezova A, Efinska-Mladenovska O, Spiroski M. Methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genotypes and haplotypes and plasma homocysteine levels in patients with occlusive artery disease and deep venous thrombosis. Acta Biochim Pol. 2008; 55(3): 587-594. PMid:18800176 DOI: https://doi.org/10.18388/abp.2008_3065
Spiroski I, Kedev S, Antov S, Arsov T, Krstevska M, Dzhekova-Stojkova S, Kostovska S, Trajkov D, Petlichkovski A, Strezova A, Efinska-Mladenovska O, Spiroski M. Association of methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genetic polymorphisms with occlusive artery disease and deep venous thrombosis in Macedonians. Croat Med J. 2008; 49(1): 39-49. http://dx.doi.org/10.3325/cmj.2008.1.39 PMid:18293456 PMCid:PMC2269242 DOI: https://doi.org/10.3325/cmj.2008.1.39
Spiroski I, Kedev S, Antov S, Trajkov D, Petlichkovski A, Dzhekova-Stojkova S, Kostovska S, Spiroski M. Investigation of SERPINE 1 genetic polymorphism in Macedonian patients with occlusive artery disease and deep venous thrombosis. Kardiol Pol. 2009; 67: 1088-1094. PMid:20017074
Kamberi B, Kamberi G. Traditional Eating Habits and Level of Homocysteine in the Acute First-Ever Ischaemic stroke. Maced J Med Sci. 2012; 5(2): 181-188. http://dx.doi.org/10.3889/MJMS.1957-5773.2012.0231 DOI: https://doi.org/10.3889/MJMS.1957-5773.2012.0231
Pezzini A, Grassi M, Del Zotto E, Archetti S, Spezi R, Vergani V, et al. Cumulative effect of predisposing genotypes and their interaction with modifiable factors of the risk of ischemic stroke in young adults. Stroke. 2005; 36: 533-539. http://dx.doi.org/10.1161/01.STR.0000155741.31499.c2 PMid:15692115 DOI: https://doi.org/10.1161/01.STR.0000155741.31499.c2
Szolnoki Z, Somogyvani F, Kondacs A, Szabo M, Fodor L, Bene J et al. Evaluation of the modifying effects of unfavorable genotypes on classical clinical risk factors for ischaemic stroke. Neurol Neurosurg Psychiatr. 2003; 74: 1615-1620. http://dx.doi.org/10.1136/jnnp.74.12.1615 PMCid:PMC1757435 DOI: https://doi.org/10.1136/jnnp.74.12.1615
Spiroski I, Kedev S, Efinska-Mladenovska O. Factor V Leiden (G1691A), Factor V R2 (A4070G), and Prothrombin (G20210A) Genetic Polymorphisms in Macedonian Patients with Occlusive Artery Disease and Deep Vein Thrombosis. SEE J Cardiol. 2015; 2015:30001. http://dx.doi.org/ 10.3889/seejca.2015.30001 DOI: https://doi.org/10.3889/seejca.2015.30001
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
